“We are at the beginning of the technology curve in pharmaceuticals.”
Jeff Galvin, CEO of American Gene Technologies (AGT), explains his ascent into the biotechnology drug development field after working closely with computers in Silicon Valley for a large part of his life. This video is the live recording of his presentation, “Can We Reprogram the Human-Computer,” at an event hosted by the Parenteral Drug Association (PDA), a leading global facilitator of science, technology, and regulatory information.
Galvin noticed an opportunity in the ability to treat and possibly cure viral diseases and cancers with the use of gene technology. Focusing on developing gene and cell therapy cures, AGT is an agent of, what is becoming, a ‘revolution in pharmaceuticals.’
Jeff Galvin explains in detail the similarities between the human body and a computer, as well as the common logic that can be used to explain how to improve each of them. Galvin describes the human body as ‘the human-computer.’ He applies Moore’s Law describing the technological advancement vs. cost ratio of the number of transmitters on a microchip to gene and cell therapy---the effectiveness of the technology doubles each year, while prices for that technology halves. As a result, the sky's the limit. Using its rapid drug delivery platform to develop gene and cell therapies at an accelerated pace, American Gene Technologies is poised to be a groundbreaking technological company of the future.
PDA published an article on Jeff Galvin and AGT and hosted this live event to provide more value to the community: Can We Program The Human Computer?
Read Biobuzz's article on the event and presentation here:
Impact of the Cell and Gene Therapy Revolution Discussed by CEO of American Gene Technologies Jeff Galvin at Recent PDA Event